ORKA
Oruka Therapeutics, Inc. trades as ORKA and has a market capitalization of $3.93 B, making it the #1587 largest US-listed company by market value. In its fiscal 2023 annual report the company posted revenue of $0.00 and net income of -$105.43M. This page tracks Oruka Therapeutics, Inc. through 1,475 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-21 |
| Insider sale notice | 144 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| SCHEDULE 13D/A | - | 2026-05-04 |
A webcast and replay of Oruka’s presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations .
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target
Leerink Partners, TD Cowen, Goldman Sachs & Co. LLC, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunning manager for the offering.
The largest companies sharing Oruka Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Oruka Therapeutics, Inc. (ORKA) has a market capitalization of $3.93 B as of 2026-06-10, ranking #1587 among US-listed companies.
Oruka Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2023.
In its latest fiscal year Oruka Therapeutics, Inc. reported a net loss of $105.43M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16